Pathos AI raises $237 million at $3 billion valuation with Bristol Myers Squibb

Pathos AI, a New York based clinical stage artificial intelligence and technology company, announced on Friday, October 23, 2026, that it closed a $237 million Series E financing round at a post money valuation of approximately $3 billion. Bristol Myers Squibb led the round, with participation from existing investors. At the same time, Pathos announced multi year strategic collaborations with Bristol Myers Squibb and Tempus AI to build a curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions.

The financing and the collaborations mark a significant expansion for a company that has spent recent months using its proprietary platform, Foundry, to assemble a clinical stage oncology portfolio. Pathos said the platform operates thousands of specialized AI agents that aggregate clinical data, genomics, biological specimen data and the competitive landscape in real time. Those agents identify the optimal next decision for a program, pinpoint biological sub populations, steer trial pivots and eliminate high risk development paths early.

Pathos now has four active clinical assets. The lead priority named by the company is JSKN016, a first in class TROP2/HER3 bispecific antibody drug conjugate that Pathos wants to move toward registrational studies. The pipeline also includes pocenbrodib in mCRPC and RRMM, AZD4241, a novel ER PROTAC partnered with AstraZeneca, and DO-2, a next generation MET kinase inhibitor. Pathos said its pipeline spans metastatic castration resistant prostate cancer, multiple myeloma, MET altered non small cell lung cancer, ER positive and HER2 negative breast cancer, and TROP2/HER3 expressing solid tumors.

The neurological effort is anchored by a five year, $55 million data license with Tempus AI. Tempus will build a de identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time and accelerate biological insight. Pathos will apply Foundry to interrogate the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials. Bristol Myers Squibb gains non exclusive strategic access to Foundry across its broader research and development portfolio, plus three year exclusive rights to use the platform for its neuroscience development programs.

Key Facts

Reuters reported on October 23, 2026 that Pathos AI had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders. Reuters also reported on October 23, 2026 that Pathos will license the data from Tempus under a five year, $55 million agreement. The financing was led by Bristol Myers Squibb and valued the New York based company at about $3 billion, with participation from existing investors.

Business Wire reported on October 23, 2026 that Bristol Myers Squibb gains non exclusive strategic access to Pathos Foundry across its broader research and development portfolio, plus three year exclusive rights to use the platform for its neuroscience development programs. That structure matters because it gives the pharmaceutical company a protected window in neuroscience while also giving it wider non exclusive access to a platform that Pathos uses across oncology and other therapeutic areas.

STAT News reported on October 23, 2026 that Pathos is expanding from oncology to neurological conditions with new datasets from Tempus AI and a partnership with Bristol Myers Squibb that will first focus on Alzheimer's treatments. STAT described Pathos as an artificial intelligence driven drug development company and noted that its Foundry model operates thousands of agents that calculate the probability of success for its clinical assets.

The company said proceeds from the $237 million round will scale Foundry's capabilities and accelerate clinical development. A key priority is JSKN016, the first in class TROP2/HER3 bispecific antibody drug conjugate, which Pathos wants to advance toward registrational studies. Capital will also support pocenbrodib in mCRPC and RRMM, AZD4241, a novel ER PROTAC partnered with AstraZeneca, and DO-2, a next generation MET kinase inhibitor.

Pathos is based in New York City. Its prior financing was a $365 million Series D at approximately $1.6 billion in May 2025. The new round therefore represents a substantial step up in valuation and adds a large pharmaceutical company as both an investor and a strategic partner.

Analysis

The most important detail in the announcement is not the size of the round by itself. It is the way the financing, the data license and the platform access fit together. Bristol Myers Squibb is not simply writing a check. It is leading the Series E, gaining non exclusive access to Foundry across its broader portfolio and securing three year exclusive rights for neuroscience development programs. Tempus is not simply selling data. It is building a longitudinal dataset from hundreds of thousands of patients with neurological conditions, a resource that Pathos will interrogate at scale.

What this really means is that Pathos has found a way to finance its platform while giving its partners specific rights that map to their strategic needs. Bristol Myers Squibb gets a protected neuroscience window and a broad view of a platform that Pathos says can estimate the probability of success for clinical assets. Pathos gets capital, a large pharmaceutical partner and a data source that it hopes will transfer the oncology playbook into Alzheimer's disease and other neurological conditions. The $55 million license is much smaller than the $237 million financing, but it is strategically central because it gives Foundry a new domain in which to operate.

The bigger picture here is that AI drug development is moving from standalone software claims toward bundled arrangements of capital, proprietary data and platform access. Pathos is not presenting Foundry as a generic tool. The company says the platform operates thousands of specialized agents that aggregate clinical data, genomics, biological specimen data and the competitive landscape in real time, then identify the optimal next decision for a program. That claim is now being tested by Bristol Myers Squibb in neuroscience and by Pathos in its own oncology pipeline.

The judgement that follows is that this deal is a validation event for Pathos, but a conditional one. The valuation jump from approximately $1.6 billion in May 2025 to approximately $3 billion in October 2026 is steep, and it depends on the company's ability to turn platform claims into clinical progress. The most visible test is JSKN016 and its path toward registrational studies. The second test is whether the Tempus dataset can help Bristol Myers Squibb and Pathos design better neuroscience trials. If those tests succeed, the bundled model could become a template. If they do not, the valuation will look ahead of the evidence.

Why It Matters

For patients with Alzheimer's disease and other neurological conditions, the collaboration points to a bet on data scale. Eric Lefkofsky, founder and chief executive of Tempus, said Alzheimer's requires unprecedented data scale and computing power. Tempus will apply infrastructure and expertise it built in oncology to create a comprehensive, de identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions. The goal is to track outcomes over time and accelerate biological insight.

For Bristol Myers Squibb, the arrangement is a way to apply advanced artificial intelligence and data science across research and development without building every capability internally. Simon Davies, senior vice president and head of data and quantitative sciences at Bristol Myers Squibb, said the investment reflects the company's commitment to applying advanced AI and data science across research and development. The three year exclusive neuroscience rights give Bristol Myers Squibb a defined period in which to use Foundry for its own neurological programs, while the non exclusive access lets it use the platform more broadly.

For the startup ecosystem, the round is a reminder that capital is still available for AI drug development companies that can pair a platform story with clinical assets and large pharmaceutical partners. Pathos has four active clinical assets and a pipeline that spans prostate cancer, multiple myeloma, lung cancer, breast cancer and TROP2/HER3 expressing solid tumors. The company also has a partnership with AstraZeneca around AZD4241, a novel ER PROTAC. That combination gives investors more to evaluate than a software demonstration.

Next Up

The next visible milestone is the advancement of JSKN016 toward registrational studies. Pathos said the proceeds will scale Foundry's capabilities and accelerate clinical development, with JSKN016 as a key priority. The company will also continue work on pocenbrodib in mCRPC and RRMM, AZD4241 with AstraZeneca and DO-2, a next generation MET kinase inhibitor. Each program gives the platform another test case and another source of clinical evidence.

The other milestone is the buildout of the Tempus neurological dataset and the start of Bristol Myers Squibb's neuroscience work under the three year exclusive rights. Pathos will apply Foundry to interrogate the dataset at scale, generate and test hypotheses on disease biology and inform the design of more targeted, adaptive clinical trials. Iker Huerga, chief executive of Pathos AI, said neurological diseases demand more than any one company can bring on its own: the best longitudinal data, AI that can reason over it at scale, and the drug development expertise to turn insight into medicines.